Get started
ProQR Therapeutics N.V.ProQR Therapeutics N.V.ProQR Therapeutics N.V.

ProQR Therapeutics N.V.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

PRQR trade ideas

🟢 NEW POSITION. $PRQR Target 7.45 for 19.39% 🟢 $PRQR Target 7.45 for 19.39% Or double position at 5.03 — On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average. I start every position with 1% of my account and build from there as needed and as possible. I am not your financial advisor. Watch my setups first before you jump in… My trade set ups work very well and they are for my personal reference and if you decide to trade them you do so at your own risk. I will gladly answer questions to the best of my knowledge but ultimately the risk is on you. I will update targets as needed. GL and happy trading. I finally added my YouTube Training Video to my profile tagline since I’m not allowed to on here. It’s a quick 15 minute training video on how to set up your chart and how to spot opportunities. So check here first but If you have questions just message me.
NASDAQ:PRQRLong
by SPYder_QQQueen_Trading
2
PRQR: Bullish Pennant (63%)Bullish Pennant (63%) Pros: Volume during post formation Descending volume during triangle formation Golden cross in blue PPS above 50MA and 200MA RS above 0 and ascending R/R ratio above 7 ATR ascending 250RSI above 50 and ascending Cons: 200MA Flat/descending Target: PT = 13.49$ Help how ever you can to keep this alive. Thank you to those who have donated Coins! Always do your own due dilligence. This is not financial advice Stay Humble, have fun, make money! Education: www.dailyfx.com
NASDAQ:PRQRLong
by LeLaf
$PRQR Announces Positive Results from Clinical Trial of QR-421aProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials. QR-421a demonstrated a concordant benefit in multiple measures of vision, including best corrected visual activity (BCVA), static perimetry, and retinal imaging (OCT) QR-421a observed to be well tolerated with no serious adverse events reported Two pivotal Phase 2/3 trials are expected to start by the end of 2021 finance.yahoo.com
NASDAQ:PRQR
by AlenCiken
Breaking the trend line after 15 months matters!Potential gain:90-120% Reward/Risk:6-9 Timeframe: 3-9 months I always try to present the charts in a simple comprehensive format to prevent any confusion. This is just my technical view, neither a fundamental comment,nor a recommendation to trade..! Please review my track record and calculate the odds for yourself..! You’re likes and comments encourage me to continue this. Stay tuned great live stream and quality content videos coming soon..! I would appreciate if you share my analysis on your own social media with your friends and beloved ones. I believe People recognize quality contents and support it to grow bigger and better.I follow Pay What You Want business model. You can support my work by the link provided in Signature part below the post.
NASDAQ:PRQRLong
by Moshkelgosha
2
ProQR Announces Positive Interim Results from Phase 1/2 ClinicalResults from the interim analysis: Efficacy data: Approximately 60% of subjects showed a clinically meaningful response in visual acuity and mobility course endpoints at three months of treatment and there was general concordance across the endpoints. Visual acuity: In the majority of patients, there was a substantive overall improvement in best corrected visual acuity (BCVA) as assessed by the Berkeley Rudimentary Vision Test (BRVT) and the Early Treatment of Diabetic Retinopathy Study (ETDRS) eye chart. In the majority of patients there was a substantive overall improvement in functional visual performance as assessed using a series of mobility courses at increasing difficulty and multiple light intensities. Full field stimulus test (FST): Improvements in visual function were supported by a meaningful increase in the ability to detect flashes of red or blue light as determined by the FST. Ocular Instability (OCI): Additionally, the majority of patients improved on nystagmus (involuntary eye movements in low vision patients) So far QR-110 was well tolerated with no serious adverse events related to treatment or procedure. All data and safety monitoring committee (DSMC) reviews were completed with no restrictions on further dose escalation or pediatric dosing. Start of Phase 2/3 pivotal “ILLUMINATE” trial The Company has agreed with the FDA to submit a protocol to start a Phase 2/3 trial that could serve as the sole registration trial, to be called "ILLUMINATE". The preliminary design for “ILLUMINATE” is a double-blind, controlled, 12-month study. The trial is expected to initially enroll 30-40 patients with LCA10 due to one or two copies of the p.Cys998X mutation and could be adaptively repowered. ir.proqr.com
NASDAQ:PRQREducation
by AlenCiken